Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials

Molecular Cancer Therapeutics

Volumn 7, Issue 9, 2008, Pages 2575-2588

  Rodon, Jordi ^a   DeSantos, Victoria ^b   Ferry Jr , Robert Jean ^c   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; 4 AMINO 5 (3 BENZYLOXYPHENYL) 7 [3 (1 PYRROLIDINYLMETHYL)CYCLOBUTYL] 7H PYRROLO[2,3 D]PYRIMIDINE; AMG 479; ANT 429; ATL 1101; AVE 1642; BIIB 022; BIOLOGICAL MARKER; BMS 536924; BMS 554417; BVP 51004; CETUXIMAB; CP 751871; DOCETAXEL; ERLOTINIB; EXEMESTANE; GEMCITABINE; HUMAN MONOCLONAL ANTIBODY; IMC A 12; IMMUNOGLOBULIN G1 ANTIBODY; INSM 18; IRINOTECAN; LAPATINIB; MK 0646; MONOCLONAL ANTIBODY; NVP AEW 541; OSI 906; PACLITAXEL; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; R 1507; R 5107; SCH 717454; SOMATOMEDIN C RECEPTOR; SORAFENIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 228;

ACNE; ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER RESEARCH; CANCER RESISTANCE; CANCER THERAPY; CD4+ T LYMPHOCYTE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DRUG MECHANISM; EWING SARCOMA; FATIGUE; FLUSHING; HEAD AND NECK CANCER; HUMAN; HYPERGLYCEMIA; LUNG NON SMALL CELL CANCER; MEDICAL RESEARCH; MOLECULAR BIOLOGY; MOLECULE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PRURITUS; RASH; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; RECEPTOR, IGF TYPE 1;

EID: 54049108939     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0265     Document Type: Review

References (131)

1. Kaplan SA, Cohen P. The somatomedin hypothesis 2007: 50 years later. J Clin Endocrinol Metab 2007;92:4529-35.
2. Hofmann F, Garcia-Echeverria C. Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov Today 2005;10:1041-7.
3. Wang Y, Ji QS, Mulvihill M, Pachter JA. Inhibition of the IGF-I receptor for treatment of cancer. Kinase inhibitors and monoclonal antibodies as alternative approaches. Recent Results Cancer Res 2007;172:59-76.
4. Ferry RJ, Jr., Cerri RW, Cohen P. Insulin-like growth factor binding proteins: new proteins, new functions. Horm Res 1999;51:53-67.
5. Mauras N, Martinez V, Rini A, Guevara-Aguirre J. Recombinant human insulin-like growth factor I has significant anabolic effects in adults with growth hormone receptor deficiency: studies on protein, glucose, and lipid metabolism. J Clin Endocrinol Metab 2000;85:3036-42.
6. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007;28:20-47.
7. Yee D. Targeting insulin-like growth factor pathways. Br J Cancer 2006;94:465-8.
8. Boulle N, Logie A, Gicquel C, Perin L, Le Bouc Y. Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancyin sporadic adrenocortical tumors. J Clin Endocrinol Metab 1998;83:1713-20.
9. Butler AA, Blakesley VA, Poulaki V, et al. Stimulation of tumor growth byrecombinant human insulin-like growth factor-I (IGF-I) is dependent on the dose and the level of IGF-I receptor expression. Cancer Res 1998;58:3021-7.
10. Imai K, Takaoka A. Comparing antibodyand small-molecule therapies for cancer. Nat Rev Cancer 2006;6:714-27.
11. Fujita-Yamaguchi Y, LeBon TR, Tsubokawa M, et al. Comparison of insulin-like growth factor I receptor and insulin receptor purified from human placental membranes. J Biol Chem 1986;261:16727-31.
12. Chen T, Wang Z, Green TP, Taylor CC. Src tyrosine kinase as a therapeutic target in ovarian cancer and multidrug-resistant ovarian cancer. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2007; San Francisco. Abstr A235.
13. Gollob JA, Wilhelm S, Carter C, Kelley SL. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 2006;33:392-406.
14. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835-44.
15. Gupta K, Krishnaswamy G , Karnad A, Peiris AN. Insulin: a novel factor in carcinogenesis. Am J Med Sci 2002;323:140-5.
16. Boyd DB. Insulin and cancer. Integr Cancer Ther 2003;2:315-29.
17. Papa V, Belfiore A. Insulin receptors in breast cancer: biological and clinical role. J Endocrinol Invest 1996;19:324-33.
18. Frittitta L, Cerrato A, Sacco MG, et al. The insulin receptor content is increased in breast cancers initiated bythree different oncogenes in transgenic mice. Breast Cancer Res Treat 1997;45:141-7.
19. Pandini G, Vigneri R, Costantino A, et al. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res 1999;5:1935-44.
20. Siddle K, Soos MA, Field CE, Nave BT. Hybrid and atypical insulin/insulin-like growth factor I receptors. Horm Res 1994;41 Suppl 2:56-64; discussion 5.
21. Pandini G, Wurch T, Akla B, et al. Functional responses and in vivo anti-tumour activityof h7C10: a humanised monoclonal antibody with neutralising activityag ainst the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors. Eur J Cancer 2007;43:1318-27.
22. Sachdev D, Singh R, Fujita-Yamaguchi Y, Yee D. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapyin breast cancer. Cancer Res 2006;66:2391-402.
23. Calzone FJ, Chung YA, Cajulis E, et al. Domain-specific mechanisms of receptor inhibition by AMG 479, a fully-human IGF1R targeted antibody. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; 2008; San Diego: AACR Philadelphia; 2008. Abstr 3994.
24. Hu YP, Dominguez I, Hauser J, et al. Characterization of in vitro and in vivo antitumor activityfor novel IGF-1R kinase inhibitors in colon cancer cells. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2007; Abstr B236.
25. Higano C, LoRusso P, Gordon M, et al. A phase I study of the recombinant human IgG1 anti-IGF-IR monoclonal antibody (Mab) IMC-A12, administered on a weekly basis to patients with advanced solid tumors: Interim analysis. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2007; San Francisco; 2007. Abstr B19.
26. Leong S, Gore L, Benjamin R, et al. A phase I study of R1507, a human monoclonal antibody IGF-1R (insulin-like growth factor receptor) antagonist given weeklyin patients with advanced solid tumors. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2007; San Francisco; 2007. Abstr A78.
27. Rodon J, Patnaik A, Stein M, et al. A phase I study of q3W R1507, a human monoclonal antibody IGF-1R (insulin-like growth factor receptor) antagonist in patients with advanced solid tumors. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2007; San Francisco (CA); 2007. Abstr A77.
28. Rothenberg ML, Poplin E, Sandler AB, et al. Phase I dose-escalation studyof the anti-IGF-IR recombinant human IgG1 monoclonal antibody (Mab) IMC-A12, administered everyo ther week to patients with advanced solid tumors AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2007; San Francisco (CA); 2007. Abstr C84.
29. Haluska P, Shaw HM, Batzel GN, et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractorysolid tumors. Clin Cancer Res 2007;13:5834-40.
30. Tolcher AW, Rothenberg ML, Rodon J, et al. A phase I pharmacokinetic and pharmacodynamic studyof AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors. J Clin Oncol 2007 ASCO Ann Meet Proc 2007;25:3002.
31. Karp DD, Paz-Ares LG, Blakely LJ, et al. Efficacy of the anti-insulin like growth factor I receptor (IGF-IR) antibody CP-751871 in combination with paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007 ASCO Ann Meet Proc Part I 2007;25:7506.
32. He G, Sung YM, Digiovanni J, Fischer SM. Thiazolidinediones inhibit insulin-like growth factor-i-induced activation of p70S6 kinase and suppress insulin-like growth factor-I tumor-promoting activity. Cancer Res 2006;66:1873-8.
33. Chou FS, Wang PS, Kulp S, Pinzone JJ. Effects of thiazolidinediones on differentiation, proliferation, and apoptosis. Mol Cancer Res 2007;5:523-30.
34. Wang T, Xu J, Yu X, Yang R, Han ZC. Peroxisome proliferator-activated receptor γ in malignant diseases. Crit Rev Oncol Hematol 2006;58:1-14.
35. Han S, Roman J. Peroxisome proliferator-activated receptor γ: a novel target for cancer therapeutics? Anticancer Drugs 2007;18:237-44.
36. Panigrahy D, Huang S, Kieran MW, Kaipainen A. PPARγ as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biol Ther 2005;4:687-93.
37. Hopfner M, Huether A, Sutter AP, et al. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. Biochem Pharmacol 2006;71:1435-48.
38. Hopfner M, Sutter AP, Huether A, Baradari V, Scherubl H. Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer. World J Gastroenterol 2006;12:5635-43.
39. Martins AS, Mackintosh C, Martin DH, et al. Insulin-like growth factor I receptor pathwayinhi bition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res 2006;12:3532-40.
40. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004;5:221-30.
41. Scotlandi K, Manara MC, Nicoletti G, et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005;65:3868-76.
42. Rochester MA, Riedemann J, Hellawell GO, Brewster SF, Macaulay VM. Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ther 2005;12:90-100.
43. Turner BC, Haffty BG, Narayanan L, et al. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 1997;57:3079-83.
44. Yu D, Watanabe H, Shibuya H, Miura M. Redundancy of radio-resistant signaling pathways originating from insulin-like growth factor I receptor. J Biol Chem 2003;278:6702-9.
45. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006;3:269-80.
46. Nahta R, Yuan LX, Du Y, Esteva FJ. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther 2007;6:667-74.
47. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005;65:11118-28.
48. Youngren JF, Gable K, Penaranda C, et al. Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells. Breast Cancer Res Treat 2005;94:37-46.
49. Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002;62:200-7.
50. Barr S, Russo S, Buck E, et al. The EGFR antagonist, erlotinib, combined with a small molecule inhibitor of IGF-1R acts synergistically to inhibit proliferation and induce apoptosis in ovarian and HNSCC cells. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2007; San Francisco (CA); 2007. Abstr A130.
51. Buck E, Eyzaguirre A, Rosenfeld-Franklin M, et al. Inhibition of IGF-1R by OSI-9 06 potentiates efficacy of various molecular targeted agents by blocking feedback loops converging at the level of IRS-1. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2007; San Francisco (CA); 2007. Abstr PR-1.
52. Lu D, Zhang H, Koo H, et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 2005;280:19665-72.
53. Tonra J DD, Corcoran E, Li H, et al. Combined antibody mediated inhibition of IGF-IR, EGFR, and VEGFR2 for more consistent and greater antitumor effects. Eur J Cancer Suppl 2006;4:64-5.
54. Wu KD, Zhou L, Burtrum D, Ludwig DL, Moore MA. Antibody targeting of the insulin-like growth factor I receptor enhances the antitumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis. Cancer Immunol Immunother 2007;56:343-57.
55. Reinmuth N, Fan F, Liu W, et al. Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest 2002;82:1377-89.
56. Divisova J, Kuiatse I, Lazard Z, et al. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat 2006;98:315-27.
57. Friend KE. Cancer and the potential place for growth hormone receptor antagonist therapy. Growth Horm IGF Res 2001;11 Suppl A:S121-3.
58. Schally AV, Varga JL, Engel JB. Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab 2008;4:33-43.
59. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400.
60. Feng Y, Zhu Z, Xiao X, Weitman SD, Dimitrov DS. Depleting soluble ligand (IGF-II) in solid tumor (human breast cancer xenograft) by ligand-specific human monoclonal antibody. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2007; San Francisco (CA); 2007 Abstr A59.
61. Feng Y, Zhu Z, Xiao X, et al. Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function. Mol Cancer Ther 2006;5:114-20.
62. Goya M, Miyamoto S, Nagai K, et al. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice bya ligand-specific antibodyto human insulin-like growth factors. Cancer Res 2004;64:6252-8.
63. Alami N, Li Z, Shiry L, Leyland-Jones B. Inhibition of mTOR and targeting insulin-like growth factor I synergistically enhance Taxol induced cytotoxicity in estrogen receptor positive breast cancer cells AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2007; San Francisco (CA); 2007. Abstr A54.
64. Cleary MP, Hu X, Grossmann ME, et al. Prevention of mammary tumorigenesis by intermittent caloric restriction: does caloric intake during refeeding modulate the response? Exp Biol Med (Maywood) 2007;232:70-80.
65. Thomson CA, Rock CL, Giuliano AR, et al. Longitudinal changes in bodyweight and body composition among women previously treated for breast cancer consuming a high-vegetable, fruit and fiber, low-fat diet. Eur J Nutr 2005;44:18-25.
66. Pierce JP, Natarajan L, Caan BJ, et al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial. JAMA 2007;298:289-98.
67. Ingle JN, Suman VJ, Kardinal CG, et al. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer 1999;85:1284-92.
68. Canobbio L, Cannata D, Miglietta L, Boccardo F. Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: clinical activity and effect on insulin-like growth factor-I (IGF-I) levels. Anticancer Res 1995;15:2687-90.
69. Bajetta E, Procopio G, Ferrari L, et al. A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma. Cancer 2002;94:299-304.
70. Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, et al. Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial. World J Gastroenterol 2007;13:3164-70.
71. Mitsiades CS, Bogdanos J, Karamanolakis D, et al. Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer. Anticancer Res 2006;26:3693-700.
72. Pollak MN, Schally AV. Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med 1998;217:143-52.
73. Weckbecker G, Liu R, Tolcsvai L, Bruns C. Antiproliferative effects of the somatostatin analogue octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro. Cancer Res 1992;52:4973-8.
74. Huynh H, Pollak M. Enhancement of tamoxifen-induced suppression of insulin-like growth factor I gene expression and serum level by a somatostatin analogue. Biochem Biophys Res Commun 1994;203:253-9.
75. Yin D, Vreeland F, Schaaf LJ, et al. Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. Clin Cancer Res 2007;13:1000-9.
76. Kurmasheva RT, Boltz C, Phelps D, Morton CL, Houghton PJ. Combination of CP-751871, a human monoclonal antibody against the IGF-1 receptor, with rapamycin results in a highly effective therapy for xenografts derived from childhood sarcomas. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2007; San Francisco (CA); 2007. Abstr C172.
77. Zitzmann K, De Toni EN, Brand S, et al. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 2007;85:54-60.
78. Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006;95:1148-54.
79. Vashist YK, Kalinina T, Quast J, et al. HSP90 inhibition is a potential therapeutic strategy in treatment of adenocarcinoma of the esophagus. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2007; San Francisco (CA); 2007. Abstr C81.
80. Buck E, Eyzaguirre A, Franklin M, et al. The EGFR inhibitor erlotinib sensitizes tumor cells to IGF-1 receptor inhibition by promoting Akt signaling through the IGF-1R-IRS1-Akt axis. AACR Annual Meeting; 2007; Los Angeles (CA); 2007. Abstr 7.
81. Morali OG, Delmas V, Moore R, et al. IGF-II induces rapid β-catenin relocation to the nucleus during epithelium to mesenchyme transition. Oncogene 2001;20:4942-50.
82. Barr S, Thomson S, Buck E, et al. Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions. Clin Exp Metastasis 2008.
83. Thomson S, Buck E, Petti F, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 2005;65:9455-62.
84. Huang F HW, Hafezi R, Han X, et al. Identification of sensitivity markers for BMS-536924, an inhibitor for insulin-like growth factor-1 receptor. J Clin Oncol ASCO Ann Meet Proc Part I 2007;25:3506.
85. Seraj J, Tsai M, Seiberling M, Cutler D. Evaluation of safety and pharmacokinetics of a fully human IGF-1 receptor antibody, SCH 717454, in healthy volunteers. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2007; San Francisco (CA); 2007. Abstr A72.
86. Pollak MN LM, Lipton A, Demers L, et al. Pharmacodynamic properties of the anti-IGF-IR monoclonal antibody CP-751,871 in cancer patients. J Clin Oncol 2007 ASCO Ann Meet Proc 2007;25:3587.
87. Lee SH, Li C, Zha J, et al. Understanding pharmacokinetics and pharmacodynamics relationship of anti-IGF1R antibody in vivo. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; 2008; San Diego (CA): AACR Philadelphia (PA); 2008. Abstr 3017.
88. de Bono JS, Attard G, Adjei A, et al. Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res 2007;13:3611-6.
89. Ratain MJ, Napoli KL, Knightley MK, et al. A phase 1b study of oral rapamycin (sirolimus) in patients with advanced malignancies. J Clin Oncol, ASCO Ann Meet Proc 2007;25. Abstr 3510.
90. Kaufman SA, Pitts TM, Serkova NJ, Stephens A, Eckhardt G, Leong S. In vitro assessment of the IGF-1R inhibitor, PQIP, alone and in combination with chemotherapy, against human colorectal cancer cell lines: Antiproliferative, molecular, and metabolic effects. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2007; San Francisco (CA): Philadelphia (PA); 2007. Abstr B44.
91. Braiteh F, Kurzrock R. Uncommon tumors and exceptional therapies: paradox or paradigm? Mol Cancer Ther 2007;6:1175-9.
92. Moody G, Mitchell P, Cajulis E, et al. AMG479, a fully human anti IGF-1 receptor monoclonal antibody, is efficacious against Ewing's sarcoma and osteosarcoma xenografts. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2007; San Francisco (CA); 2007. Abstr A64.
93. Manara MC, Landuzzi L, Nanni P, et al. Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing's sarcoma. Clin Cancer Res 2007;13:1322-30.
94. Hartmann W, Czerwitzki J, Endl E, et al. Insulin-like growth factor-I receptor signals proliferation in synovial sarcoma. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; 2008; San Diego (CA): AACR Philadelphia (PA); 2008. Abstr 5100.
95. Olmos D, Molife R, Okuno S, et al. Safety, tolerability and preliminary efficacy of the anti-IGF-IR monoclonal antibody CP-751,871 in patients with sarcomas and adrenocortical tumors AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2007; San Francisco (CA); 2007. Abstr A63.
96. Cohen BD, Baker DA, Soderstrom C, et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871 . Clin Cancer Res 2005;11:2063-73.
97. Burtrum D, Zhu Z, Lu D, et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 2003;63:8912-21.
98. Barnes CJ, Kumar R. Novel mechanistic insights from a preclinical model targeting insulin-like growth factor receptor 1. AACR Annual Meeting; 2006; Washington (DC); 2006. Abstr B-247.
99. Rowinsky EK, Youssoufian H, Tonra JR, et al. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 2007;13:5549-55s.
100. Schnitzer T KK, Rebers F, Van Vugt M, et al. Characterization of a recombinant, fully human monoclonal antibody directed against the human insulin-like growth factor1 receptor. Eur J Cancer Suppl 2006;4:66.
101. Beltran PJ, Mitchell P, Moody G, et al. AMG-479, a fully human anti IGF-1 receptor antibody, inhibits PI3K/Akt signaling and exerts potent antitumor effects in combination with EGF-R inhibitors in pancreatic xenograft models. ASCO Gastrointestinal Cancers Symposium 2007; 2007. Abstr 208.
102. Beltran PJ, Mitchell P, Hwang D, et al. Inhibition of endocrine IGF-1 signaling in normal murine tissues and human tumor xenografts with AMG 479, a fully human anti IGF-1R monoclonal antibody AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2007; San Francisco, (CA); 2007. Abstr A67.
103. Maloney EK, McLaughlin JL, Dagdigian NE, et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 2003;63:5073-83.
104. Bladt F, Vrignaud P, Chiron M, et al. Pre-clinical evaluation of the anti-tumor activity of the IGF1R-specific antibody AVE1642. AACR Annual Meeting; 2006; Washington (DC); 2006. Abstr 1225.
105. Geoerger B, Daudigeous E, DeBussche L, et al. The anti insulin-like growth factor 1 receptor (IGF1-R) antibody AVE1642 exhibits anti-tumor activity against neuroblastoma cell lines and xenografts. AACR Annual Meeting; 2006; Washington (DC); 2006. Abstr 1222.
106. Goetsch L, Gonzalez A, Leger O, et al. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 2005;113:316-28.
107. Goetsch L, Gonzalez A, Fournier M, et al. Insulin-like Growth Factor Receptor Type I down regulation induced by the humanized Antibody h7C10 (A2CHM). AACR Annual Meeting; 2006; Washington (DC); 2006. Abstr 1187.
108. Wurch T PG, Akla B, Corvaia N, Belfiore A, Goetsch L. In vitro and in vivo inhibition of functional responses at insulin-like growth factor-1/insulin hybrid receptors by h7C10, a novel humanized anti-IGF-1R monoclonal antibody. Eur J Cancer Suppl 2006;4:61.
109. Hariharan K, Dong J, Demarest S, et al. BIIB022, a fully human nonglycosylated γ4P antibody targeting IGF-1R for cancer therapy. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2007; San Francisco (CA); 2007. Abstr B210.
110. Dong J, Tamraz S, Berquist L, et al. BIIB022, a human antibody targeting human insulin-like growth factor-1 receptor (IGF-1R), enhances the anti-tumor activities of Tarceva in non-small cell lung carcinoma (NSCLC) and Rapamycin in sarcoma cell lines. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; 2008. Abstr 4002.
111. Ji QS, Mulvihill M, Franklin M, et al. Properties of small molecule IGF-IR kinase inhibitors in preclinical models. AACR Annual Meeting; 2007; Los Angeles (CA); 2007. Abstr 30.9.
112. Rosenfeld-Franklin M, Cooke A, Pirritt C, et al. In vivo evaluation of OSI-906, a novel small molecule kinase inhibitor of the insulin-like growth factor-1 receptor (IGF-1R) AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2007. Abstr B244.
113. Ji Q, Mulvihill MJ, Rosenfeld-Franklin M, et al. Preclinical characterization of OSI-906: A novel IGF-1R kinase inhibitor in clinical trials. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2007. Abstr C192.
114. Mulvihill MJ, Ji QS, Rosenfeld-Franklin M, et al. The discovery of OSI-906: A novel, potent, orally bioavailable imidazopyrazine-derived insulin-like growth factor-I receptor (IGF-1R) inhibitor with antitumor activity. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; 2008. Abstr 4893.
115. Aftab D. Simultaneous inhibition of IGF1R and Src family kinases causes tumor growth inhibition and tumor regression in xenograft models. Eur J Cancer Suppl 2006;4:178.
116. Toretsky JA, Steinberg SM, Thakar M, et al. Insulin-like growth factor type 1 (IGF-1) and IGF binding protein-3 in patients with Ewing sarcoma family of tumors. Cancer 2001;92:2941-7.
117. Warshamana-Greene GS, Litz J, Buchdunger E, et al. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin Cancer Res 2005;11:1563-71.
118. Garcia-Echeverria C, Pearson MA, Marti A, et al. In vivo antitumor activityof NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004;5:231-9.
119. Esparís-Ogando AR-B, Borges R, Ferreira J, Pandiella LA, Ocana A. Insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 is active in breast cancer cells and enhances growth inhibition by herceptin through an increase in cell cycle arrest. J Clin Oncol (Meeting Abstracts) 2007;25:21077-.
120. Slomiany MG, Black LA, Kibbey MM, et al. Insulin-like growth factor-1 receptor and ligand targeting in head and neck squamous cell carcinoma. Cancer Lett 2007;248:269-79.
121. Shu Y, Yin Y, Guo G, Gu Y, Liu L, Wang R. Increasing tripartite cooperation of ER-α, c-Src, and IGF-1R plays an important role in tamoxifen resistance. In: Oncology JoC, editor. ASCO Annual Meeting 2007 June 20 2007. Abstr 18S.
122. Haluska P, Carboni JM, Loegering DA, et al. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res 2006;66:362-71.
123. Girnita A, Vasilcanu R, Vasilcanu D, Axelson M, Girnita L. Short time PPP treatment effects on IGF1R signaling cascade. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; 2008. Abstr 3500.
124. Girnita L, Girnita A, Larsson O. IGF-1R inhibition through ubiquitination. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; 2008. Abstr 3502.
125. Best C, Ludwig CL, Steeg PS. Breast cancer cell lines resistant to either tamoxifen or Herceptin exhibit sensitivity to the anti-IGF receptor antibody A12 in vitro. AACR Annual Meeting; 2006. Abstr 1228.
126. Ji QS, Mulvihill M, Franklin M, et al. A novel, potent and selective IGF-1R small molecule inhibitor potentiates erlotinib activityin NSCLC cell lines in vitro and in vivo. AACR Annual Meeting; 2006.
127. Wu JD, Odman A, Higgins LM, et al. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res 2005;11:3065-74.
128. Barr SM, Buck E, Thomson S, et al. The combination of small molecule inhibitors of EGFR and IGF-1R is synergistic in HNSCC and ovarian cancer cell lines. AACR Annual Meeting; 2007. Abstr 2557.
129. Benini S, Manara MC, Baldini N, et al. Inhibition of insulin-like growth factor I receptor increases the antitumor activityof doxorubicin and vincristine against Ewing's sarcoma cells. Clin Cancer Res 2001;7:1790-7.
130. Wu JD, Haugk K, Coleman I, et al. Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors. Clin Cancer Res 2006;12:6153-60.
131. Allen GW, Saba C, Armstrong EA, et al. Insulin-like growth factor-I receptor signaling blockade combined with radiation. Cancer Res 2007;67:1155-62.